By knocking down RAB5B in MCF-7and SK-Hep-1cells, it is strongly proved that RAB5B significantly inhibits the proliferation and migration of breast cancer cells, highlighting its potential as a target for anti-breast cancer drugs. Here, RAB5B is linked to breast carcinoma.